HAP Trading’s Myriad Genetics MYGN Stock Holding History

HAP Trading’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$10K	–	2221
2022 Q1	$10K	Buy	+10,000	New	+$256K	﹤0.01%	1783
2014 Q1	–	Sell	-45,400	Closed	-$6K	–	1268
2013 Q4	$6K	Buy	+45,400	New	+$1.15M	﹤0.01%	1070

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HAP Trading's MYGN Position: Q3 2017 in Review

HAP Trading sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 13,942 shares — an estimated $360K sold.

HAP Trading first reported a position in MYGN in Q3 2013 and held it in 6 quarters. The position peaked at $4.17M in Q3 2013. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

HAP Trading reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
HAP Trading sold 13,942 Myriad Genetics shares in Q3 2017, an estimated $360K.
HAP Trading first reported a position in Myriad Genetics in Q3 2013 and held it in 6 quarters.
HAP Trading's Myriad Genetics position peaked at $4.17M in Q3 2013.
220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on HAP Trading's 13F filing for Q3 2017, filed 8 Nov 2017.